{"entity":{"id":"palacaparib","kind":"drug","name":"Palacaparib","aka":[],"tldr":"Palacaparib is an experimental DNA-repair inhibitor designed to reach the brain and selectively block PARP1.","summary":"The primary discovery publication identifies AZD9574/palacaparib as a brain-penetrant PARP1-selective inhibitor. CERTIS1 (NCT05417594) is recruiting with 695 planned participants and was updated in October 2026. It studies monotherapy and combinations including temozolomide, trastuzumab deruxtecan and datopotamab deruxtecan. A registry-wide recruiting state does not confirm a specific local site or available slot. Brain exposure and PARP1 selectivity are development features; human superiority, marrow sparing and a breast-cancer indication are not established.","status":"phase-2","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov: trials of Palacaparib","url":"https://clinicaltrials.gov/search?intr=AZD9574"},{"label":"ClinicalTrials.gov NCT05417594","url":"https://clinicaltrials.gov/study/NCT05417594"},{"label":"Primary discovery publication","url":"https://doi.org/10.1021/acs.jmedchem.4c01725"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","nsclc","endometrial"],"sections":[],"technologies":[],"targets":["parp"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07181161","nct05797168","nct05123482","nct07590934","nct05417594"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"AZD9574","modality":"small molecule","mechanism":"PARP1-selective, brain-penetrant inhibitor and trapper (AZD9574).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/palacaparib/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","route":"/trials/nct05123482/"},{"id":"nct05797168","kind":"trial","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","route":"/trials/nct05797168/"},{"id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","route":"/trials/nct07590934/"},{"id":"nct07181161","kind":"trial","name":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","route":"/trials/nct07181161/"},{"id":"nct05417594","kind":"trial","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","route":"/trials/nct05417594/"}]}}